E Gane

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. ncbi request reprint Management of chronic viral hepatitis before and after renal transplantation
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, New Zealand
    Transplantation 74:427-37. 2002
  2. doi request reprint A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis
    Peter W Angus
    Victorian Liver Transplant Unit, Austin Health, Victoria, Australia
    Hepatology 48:1460-6. 2008
  3. ncbi request reprint Liver transplantation in New Zealand: the first four years
    Ed Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    N Z Med J 115:U120. 2002
  4. ncbi request reprint Treatment of recurrent hepatitis C
    Ed Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, NZ
    Liver Transpl 8:S28-37. 2002
  5. ncbi request reprint The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Liver Transpl 9:S28-34. 2003
  6. ncbi request reprint Treatment of chronic hepatitis C in patients with renal disease
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Med J Malaysia 60:72-6. 2005
  7. ncbi request reprint Liver transplantation in chronic hepatitis B
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Med J Malaysia 60:88-9. 2005
  8. ncbi request reprint Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C
    Daniele Prati
    Ospedale A Manzoni, Lecco and IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy
    J Hepatol 44:679-85. 2006
  9. ncbi request reprint Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
  10. ncbi request reprint Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
    Vaccine 25:8585-97. 2007

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Management of chronic viral hepatitis before and after renal transplantation
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, New Zealand
    Transplantation 74:427-37. 2002
    ..Established cirrhosis with active viral infection should be considered a relative contraindication to isolated renal transplantation...
  2. doi request reprint A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis
    Peter W Angus
    Victorian Liver Transplant Unit, Austin Health, Victoria, Australia
    Hepatology 48:1460-6. 2008
    ..Yearly cost of combination adefovir/lamivudine prophylaxis was $8,290 versus $13,718 IM HBIG/lamivudine...
  3. ncbi request reprint Liver transplantation in New Zealand: the first four years
    Ed Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    N Z Med J 115:U120. 2002
    ..To summarise the transplant-related activity of the New Zealand Liver Transplant Unit over the first four years...
  4. ncbi request reprint Treatment of recurrent hepatitis C
    Ed Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, NZ
    Liver Transpl 8:S28-37. 2002
    ..9. In a recent study, posttransplant immunoprophylaxis with polyclonal hepatitis C immunoglobulin had no effect on recurrent viremia or hepatitis...
  5. ncbi request reprint The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Liver Transpl 9:S28-34. 2003
    ..The 3-year survival is <10% after the onset of hepatitis C virus-related allograft failure, compared with 60% after decompensation in immunocompetent patients...
  6. ncbi request reprint Treatment of chronic hepatitis C in patients with renal disease
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Med J Malaysia 60:72-6. 2005
  7. ncbi request reprint Liver transplantation in chronic hepatitis B
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
    Med J Malaysia 60:88-9. 2005
  8. ncbi request reprint Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C
    Daniele Prati
    Ospedale A Manzoni, Lecco and IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy
    J Hepatol 44:679-85. 2006
    ..To clarify the role and interactions of viral and host factors in inducing liver cell injury, we examined the associations of several virological and metabolic variables with serum alanine aminotransferase levels...
  9. ncbi request reprint Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
    ..HRQoL in the present population was also compared with HRQoL in patients with elevated ALT levels, observed in a previous study...
  10. ncbi request reprint Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
    Vaccine 25:8585-97. 2007
    ....
  11. ncbi request reprint Telbivudine versus lamivudine in patients with chronic hepatitis B
    Ching Lung Lai
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China
    N Engl J Med 357:2576-88. 2007
    ..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B...
  12. ncbi request reprint Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  13. ncbi request reprint Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    Liver Int 25:472-89. 2005
    ..A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update...
  14. ncbi request reprint Screening for chronic hepatitis B infection in New Zealand: unfinished business
    Edward Gane
    N Z Med J 118:U1344. 2005
  15. ncbi request reprint Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
    ....
  16. ncbi request reprint Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C
    Jens Rasenack
    Klinikum der Albert Ludwigs Universität, Freiburg, Germany
    Pharmacoeconomics 21:341-9. 2003
    ..Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a...
  17. doi request reprint Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  18. ncbi request reprint Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis
    Darrell H G Crawford
    Queensland Liver Transplant Service and The University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
    Hepatology 39:1655-62. 2004
    ..Our data suggest that iron excess in HH does not wholly depend on intestinal iron absorption but is also influenced by liver factors that moderate iron metabolism...
  19. ncbi request reprint Liver transplantation in Jehovah's Witness patients in Australasia
    Gary P Jeffrey
    Western Australian Liver Transplantation Service, Sir Charles Gairdner Hospital, Perth, WA, Australia
    Med J Aust 187:188-9. 2007
    ..To our knowledge, these are the first such cases in Australasia. The techniques used to minimise blood loss and transfusion requirements could potentially benefit all patients undergoing major surgery...
  20. ncbi request reprint Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians
    William Abbott
    New Zealand Liver Transplant Unit, Auckland City Hospital, Private Bag 92 024, Auckland, New Zealand
    Immunogenetics 59:187-95. 2007
    ..These findings are consistent with a previous report of an association between +875 IFNGCA and [tsIgE] and provide preliminary evidence of a new association with the outcome of an HBV infection...
  21. ncbi request reprint Practical difficulties in the management of hepatitis B in the Asia-Pacific region
    Rosmawati Mohamed
    Department of Medicine, University Malaya, Kuala Lumpur, Malaysia
    J Gastroenterol Hepatol 19:958-69. 2004
    ....
  22. ncbi request reprint Resolution of alcoholic neuropathy following liver transplantation
    Edward Gane
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    Liver Transpl 10:1545-8. 2004
    ..In conclusion, this case suggests that peripheral neuropathy in a patient with alcoholic cirrhosis may resolve following liver transplantation and should not constitute a contraindication to transplantation, even when it is disabling...
  23. ncbi request reprint Liver transplantation for hepatocellular carcinoma in New Zealand: a prospective intent-to-treat analysis
    Yuhji Marui
    New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
    N Z Med J 118:U1532. 2005
    ..Liver transplantation (LT) is potentially curative for early hepatocellular carcinoma (HCC) but time spent on the waiting list exposes patients to the risk of tumour progression prior to transplantation...